Neuromodulation device shows promising efficacy for neurogenic bladder
Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC
FDA approval sought for Anktiva in papillary NMIBC
App shows promise in managing lower urinary tract symptoms